Group items tagged

The goal of the program is to build a research cohort of one million or more U.S. volunteers who are engaged as partners in a longitudinal, long-term effort to transform the understanding of factors contributing to individual health and disease.

The purpose of this FOA is to solicit applications to expand research activities funded under RFA-AT-18-002 and RFA-DA-18-005 on the impact of interventions designed to improve adherence to Medication Assisted Treatment (MAT) or linking individuals with Opioid Use Disorders (OUD) who receive naloxone for the reversal of overdose to MAT within the context of states use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Expansion of research activities should increase the generalizability of findings to allow for more rapid dissemination and implementation of successful interventions. Examples of additional activities include but are not limited to adding recruitment/study sites, increasing the overall sample size, targeting under-represented populations, and adjusting for longer follow-up.

The funding is offered in conjunction with the theme of the National Symposium on Academic Palliative Care Education and Research, Quality in Palliative Care: Fusing Education, Research and Practice, being held in San Diego from October 11 to October 12, 2018. Multiple grants ranging between $5,000 and $10,000 will be awarded at the symposium. The institute encourages proposals for innovative educational and/or research projects that will expand current or future workforce knowledge leading to improved care or enhanced quality of life for seriously or chronically ill people.

NineSigma, representing a Japanese leading pharmaceutical company, seeks drug discovery projects which make use of any of the following drug discovery underlying technologies and which are in a hit discovery stage. It is preferable that the research has already started; however, proposals are welcome also from an organization with plans to start a specific project in the future. The client aims to build a drug discovery platform, which is globally competitive, through collaboration with partners. The client can provide opportunities, depending on the R&D stage and the business plan of partners, and hopes not only to foster joint research and development, but also to maximize outcome creation by licensing, support with budget, etc. to support improvement of underlying technology.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

 The purpose of this program is to support research activities that expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products. We will also consider biological products relevant to CDER (e.g., monoclonal antibodies and therapeutic proteins) for this announcement.       

Dr. Chockalingam Sivakumar and his study team at Global Mantra Innovation are seeking interested collaborators to provide SME support and site identification for a Disease Management Analytics platform on a retrospective observational study about Type-2 Diabetes Mellitus.

Through the program, grants of up to $3 million over three years will be awarded to established investigators across scientific disciplines and geographies who are positioned to make major advances in understanding the heterogeneity of systemic lupus erythematous (SLE) using highly collaborative, synergistic, and innovative approaches.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.